Aditxt (ADTX) Competitors

$1.22 -0.18 (-12.86%)

Closing price 04:00 PM Eastern

Extended Trading

$1.29 +0.07 (+6.07%)

As of 07:59 PM Eastern

ADTX vs. ONCO, AMPE, PTPI, LIPO, and VINC

Should you buy Aditxt stock or one of its competitors? MarketBeat compares Aditxt with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Aditxt include Onconetix (ONCO), Ampio Pharmaceuticals (AMPE), Petros Pharmaceuticals (PTPI), Lipella Pharmaceuticals (LIPO), and Vincerx Pharma (VINC). These companies are all part of the "pharmaceutical products" industry.

How does Aditxt compare to Onconetix?

Aditxt (NASDAQ:ADTX) and Onconetix (NASDAQ:ONCO) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their dividends, analyst recommendations, valuation, earnings, risk, institutional ownership, profitability and media sentiment.

In the previous week, Aditxt had 2 more articles in the media than Onconetix. MarketBeat recorded 6 mentions for Aditxt and 4 mentions for Onconetix. Aditxt's average media sentiment score of -0.43 beat Onconetix's score of -0.50 indicating that Aditxt is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Aditxt	0 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral
Onconetix	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Negative

Onconetix has higher revenue and earnings than Aditxt. Aditxt is trading at a lower price-to-earnings ratio than Onconetix, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aditxt	N/A	N/A	-$41.71M	-$11.10 thousand	N/A
Onconetix	$810K	0.99	-$14.03M	$1.14	1.07

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aditxt	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Onconetix	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

15.5% of Aditxt shares are owned by institutional investors. Comparatively, 23.9% of Onconetix shares are owned by institutional investors. 0.0% of Aditxt shares are owned by company insiders. Comparatively, 0.3% of Onconetix shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Onconetix has a net margin of -1,316.28% compared to Aditxt's net margin of -360,152.50%. Onconetix's return on equity of -101.08% beat Aditxt's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aditxt	-360,152.50%	-839.49%	-97.56%
Onconetix	-1,316.28%	-101.08%	-47.34%

Aditxt has a beta of 1.08, suggesting that its stock price is 8% more volatile than the broader market. Comparatively, Onconetix has a beta of 3.01, suggesting that its stock price is 201% more volatile than the broader market.

Summary

Onconetix beats Aditxt on 10 of the 12 factors compared between the two stocks.

How does Aditxt compare to Ampio Pharmaceuticals?

Aditxt (NASDAQ:ADTX) and Ampio Pharmaceuticals (NYSE:AMPE) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, media sentiment, dividends, analyst recommendations, earnings, risk, profitability and valuation.

Aditxt has a beta of 1.08, indicating that its share price is 8% more volatile than the broader market. Comparatively, Ampio Pharmaceuticals has a beta of 5.96, indicating that its share price is 496% more volatile than the broader market.

Ampio Pharmaceuticals has a net margin of 0.00% compared to Aditxt's net margin of -360,152.50%. Ampio Pharmaceuticals' return on equity of 0.00% beat Aditxt's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aditxt	-360,152.50%	-839.49%	-97.56%
Ampio Pharmaceuticals	N/A	N/A	N/A

Ampio Pharmaceuticals is trading at a lower price-to-earnings ratio than Aditxt, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aditxt	N/A	N/A	-$41.71M	-$11.10 thousand	N/A
Ampio Pharmaceuticals	N/A	N/A	-$8.63M	-$11.01	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aditxt	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Ampio Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

15.5% of Aditxt shares are owned by institutional investors. Comparatively, 5.7% of Ampio Pharmaceuticals shares are owned by institutional investors. 0.0% of Aditxt shares are owned by company insiders. Comparatively, 3.3% of Ampio Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

In the previous week, Aditxt had 6 more articles in the media than Ampio Pharmaceuticals. MarketBeat recorded 6 mentions for Aditxt and 0 mentions for Ampio Pharmaceuticals. Ampio Pharmaceuticals' average media sentiment score of 0.00 beat Aditxt's score of -0.43 indicating that Ampio Pharmaceuticals is being referred to more favorably in the news media.

Company	Overall Sentiment
Aditxt	Neutral
Ampio Pharmaceuticals	Neutral

Summary

Ampio Pharmaceuticals beats Aditxt on 8 of the 12 factors compared between the two stocks.

How does Aditxt compare to Petros Pharmaceuticals?

Aditxt (NASDAQ:ADTX) and Petros Pharmaceuticals (NASDAQ:PTPI) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, institutional ownership, media sentiment, profitability, valuation, dividends, analyst recommendations and risk.

In the previous week, Aditxt had 6 more articles in the media than Petros Pharmaceuticals. MarketBeat recorded 6 mentions for Aditxt and 0 mentions for Petros Pharmaceuticals. Petros Pharmaceuticals' average media sentiment score of 0.00 beat Aditxt's score of -0.43 indicating that Petros Pharmaceuticals is being referred to more favorably in the news media.

Company	Overall Sentiment
Aditxt	Neutral
Petros Pharmaceuticals	Neutral

Petros Pharmaceuticals has higher revenue and earnings than Aditxt. Petros Pharmaceuticals is trading at a lower price-to-earnings ratio than Aditxt, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aditxt	N/A	N/A	-$41.71M	-$11.10 thousand	N/A
Petros Pharmaceuticals	$5.11M	0.04	-$8.16M	-$1.64	N/A

Aditxt has a beta of 1.08, meaning that its share price is 8% more volatile than the broader market. Comparatively, Petros Pharmaceuticals has a beta of 1.91, meaning that its share price is 91% more volatile than the broader market.

15.5% of Aditxt shares are owned by institutional investors. Comparatively, 12.3% of Petros Pharmaceuticals shares are owned by institutional investors. 0.0% of Aditxt shares are owned by insiders. Comparatively, 12.3% of Petros Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Petros Pharmaceuticals has a net margin of 0.00% compared to Aditxt's net margin of -360,152.50%. Petros Pharmaceuticals' return on equity of -78.22% beat Aditxt's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aditxt	-360,152.50%	-839.49%	-97.56%
Petros Pharmaceuticals	N/A	-78.22%	-23.50%

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aditxt	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Petros Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Summary

Petros Pharmaceuticals beats Aditxt on 9 of the 13 factors compared between the two stocks.

How does Aditxt compare to Lipella Pharmaceuticals?

Lipella Pharmaceuticals (NASDAQ:LIPO) and Aditxt (NASDAQ:ADTX) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their earnings, risk, valuation, profitability, dividends, analyst recommendations, media sentiment and institutional ownership.

74.3% of Lipella Pharmaceuticals shares are owned by institutional investors. Comparatively, 15.5% of Aditxt shares are owned by institutional investors. 32.1% of Lipella Pharmaceuticals shares are owned by company insiders. Comparatively, 0.0% of Aditxt shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Lipella Pharmaceuticals has higher revenue and earnings than Aditxt. Lipella Pharmaceuticals is trading at a lower price-to-earnings ratio than Aditxt, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lipella Pharmaceuticals	$536.36K	1.21	-$5.02M	-$2.42	N/A
Aditxt	N/A	N/A	-$41.71M	-$11.10 thousand	N/A

Lipella Pharmaceuticals has a net margin of -988.83% compared to Aditxt's net margin of -360,152.50%. Lipella Pharmaceuticals' return on equity of -224.08% beat Aditxt's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Lipella Pharmaceuticals	-988.83%	-224.08%	-172.88%
Aditxt	-360,152.50%	-839.49%	-97.56%

In the previous week, Aditxt had 6 more articles in the media than Lipella Pharmaceuticals. MarketBeat recorded 6 mentions for Aditxt and 0 mentions for Lipella Pharmaceuticals. Lipella Pharmaceuticals' average media sentiment score of 0.00 beat Aditxt's score of -0.43 indicating that Lipella Pharmaceuticals is being referred to more favorably in the media.

Company	Overall Sentiment
Lipella Pharmaceuticals	Neutral
Aditxt	Neutral

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lipella Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Aditxt	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Lipella Pharmaceuticals has a beta of 0.83, suggesting that its share price is 17% less volatile than the broader market. Comparatively, Aditxt has a beta of 1.08, suggesting that its share price is 8% more volatile than the broader market.

Summary

Lipella Pharmaceuticals beats Aditxt on 8 of the 13 factors compared between the two stocks.

How does Aditxt compare to Vincerx Pharma?

Aditxt (NASDAQ:ADTX) and Vincerx Pharma (NASDAQ:VINC) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their profitability, analyst recommendations, institutional ownership, risk, earnings, media sentiment, dividends and valuation.

Vincerx Pharma is trading at a lower price-to-earnings ratio than Aditxt, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aditxt	N/A	N/A	-$41.71M	-$11.10 thousand	N/A
Vincerx Pharma	N/A	N/A	-$40.16M	-$5.31	N/A

Aditxt has a beta of 1.08, meaning that its share price is 8% more volatile than the broader market. Comparatively, Vincerx Pharma has a beta of 1.46, meaning that its share price is 46% more volatile than the broader market.

Vincerx Pharma has a net margin of 0.00% compared to Aditxt's net margin of -360,152.50%. Vincerx Pharma's return on equity of -248.33% beat Aditxt's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aditxt	-360,152.50%	-839.49%	-97.56%
Vincerx Pharma	N/A	-248.33%	-132.73%

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aditxt	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Vincerx Pharma	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

In the previous week, Aditxt had 6 more articles in the media than Vincerx Pharma. MarketBeat recorded 6 mentions for Aditxt and 0 mentions for Vincerx Pharma. Vincerx Pharma's average media sentiment score of 0.00 beat Aditxt's score of -0.43 indicating that Vincerx Pharma is being referred to more favorably in the news media.

Company	Overall Sentiment
Aditxt	Neutral
Vincerx Pharma	Neutral

15.5% of Aditxt shares are held by institutional investors. Comparatively, 44.0% of Vincerx Pharma shares are held by institutional investors. 0.0% of Aditxt shares are held by company insiders. Comparatively, 15.6% of Vincerx Pharma shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Summary

Vincerx Pharma beats Aditxt on 8 of the 12 factors compared between the two stocks.

Get Aditxt News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ADTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ADTX vs. The Competition

Export

Metric	Aditxt	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$50K	$3.02B	$6.34B	$12.29B
Dividend Yield	N/A	1.97%	2.80%	5.36%
P/E Ratio	0.00	17.78	20.94	25.46
Price / Sales	N/A	251.59	521.00	73.83
Price / Cash	N/A	56.99	43.18	55.00
Price / Book	0.00	4.58	9.98	7.00
Net Income	-$41.71M	$74.99M	$3.55B	$335.16M
7 Day Performance	-32.36%	-2.36%	0.42%	-0.29%
1 Month Performance	-85.33%	-4.13%	-0.05%	1.15%
1 Year Performance	-100.00%	36.31%	35.06%	34.79%

Aditxt Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ADTX Aditxt	0.8349 of 5 stars	$1.22 -12.9%	N/A	-100.0%	$50K	N/A	N/A	60	Earnings Report Stock Split
ONCO Onconetix	1.3394 of 5 stars	$0.38 -6.2%	N/A	-99.7%	$249K	$810K	N/A	12	Stock Split
AMPE Ampio Pharmaceuticals	N/A	$0.18 flat	N/A	+5,806.5%	$208K	N/A	N/A	20
PTPI Petros Pharmaceuticals	N/A	$0.01 -1.5%	N/A	-94.4%	$199K	$5.11M	N/A	20	Gap Down
LIPO Lipella Pharmaceuticals	N/A	$0.04 flat	N/A	-95.5%	$195K	$536.36K	N/A	4	Gap Down High Trading Volume

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ADTX) was last updated on 5/21/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Aditxt (ADTX) Competitors

ADTX vs. ONCO, AMPE, PTPI, LIPO, and VINC

How does Aditxt compare to Onconetix?

Summary

How does Aditxt compare to Ampio Pharmaceuticals?

Summary

How does Aditxt compare to Petros Pharmaceuticals?

Summary

How does Aditxt compare to Lipella Pharmaceuticals?

Summary

How does Aditxt compare to Vincerx Pharma?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ADTX vs. The Competition

Aditxt Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Aditxt (ADTX) Competitors

ADTX vs. ONCO, AMPE, PTPI, LIPO, and VINC

How does Aditxt compare to Onconetix?

Does the media refer more to ADTX or ONCO?

Which has better valuation and earnings, ADTX or ONCO?

Do analysts recommend ADTX or ONCO?

Do insiders and institutionals believe in ADTX or ONCO?

Is ADTX or ONCO more profitable?

Which has more volatility & risk, ADTX or ONCO?

Summary

How does Aditxt compare to Ampio Pharmaceuticals?

Which has more volatility and risk, ADTX or AMPE?

Is ADTX or AMPE more profitable?

Which has preferable valuation & earnings, ADTX or AMPE?

Do analysts prefer ADTX or AMPE?

Do insiders & institutionals have more ownership in ADTX or AMPE?

Does the media refer more to ADTX or AMPE?

Summary

How does Aditxt compare to Petros Pharmaceuticals?

Does the media prefer ADTX or PTPI?

Which has better earnings & valuation, ADTX or PTPI?

Which has more risk and volatility, ADTX or PTPI?

Do insiders and institutionals have more ownership in ADTX or PTPI?

Is ADTX or PTPI more profitable?

Do analysts rate ADTX or PTPI?

Summary

How does Aditxt compare to Lipella Pharmaceuticals?

Do insiders & institutionals hold more shares of LIPO or ADTX?

Which has better valuation and earnings, LIPO or ADTX?

Is LIPO or ADTX more profitable?

Does the media refer more to LIPO or ADTX?

Do analysts recommend LIPO or ADTX?

Which has more risk & volatility, LIPO or ADTX?

Summary

How does Aditxt compare to Vincerx Pharma?

Which has stronger valuation and earnings, ADTX or VINC?

Which has more volatility and risk, ADTX or VINC?

Is ADTX or VINC more profitable?

Do analysts rate ADTX or VINC?

Does the media refer more to ADTX or VINC?

Do insiders and institutionals believe in ADTX or VINC?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ADTX vs. The Competition

Aditxt Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools